Bodenstein, David F.
Siebiger, Gabriel
Zhao, Yimu
Clasky, Aaron J.
Mukkala, Avinash N.
Beroncal, Erika L.
Banh, Lauren
Aslostovar, Lili
Brijbassi, Sonya
Hogan, Sarah E.
McCully, James D.
Mehrabian, Mohadeseh
Petersen, Thomas H.
Robinson, Lisa A.
Walker, Melanie
Zachos, Constantine
Viswanathan, Sowmya
Gu, Frank X.
Rotstein, Ori D.
Cypel, Marcelo
Radisic, Milica
Andreazza, Ana C. http://orcid.org/0000-0002-4323-7273
,
Funding for this research was provided by:
Medicine by Design
MITO2i
Article History
Received: 12 December 2023
Accepted: 27 May 2024
First Online: 31 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: SEH and TPJ are paid employees of United Therapeutics. LA and MM are paid employees of the Centre for Commercialization of Regenerative Medicine. MR and YZ are inventors on a patent describing Biowire II heart-on-a-chip technology that is licensed to Valo Health. They receive royalty payments. ACA is the founder and scientific director for MITO2i. No author has or will receive financial incentive of any kind in relation to the technology described herein.